MarketCap
Facebook
X
TelegramAerpio Pharmaceuticals, Inc. Gesamtverbindlichkeiten 2011-2026 | ARPO
Gesamtverbindlichkeiten Jährlich Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 1.87 M | 3.4 M | 5.46 M | 3.59 M | 230 K | 205 K | 160 K | 133 K | 104 K | 74.8 K |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.46 M | 74.8 K | 1.52 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M |  USA |
 |
argenx SE
ARGX
|
704 M | $ 843.68 | 1.22 % | $ 25 B |  Niderland |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M |  Canada |
 |
Anavex Life Sciences Corp.
AVXL
|
8.95 M | $ 4.13 | 5.36 % | $ 352 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
38.7 M | $ 3.19 | 11.93 % | $ 180 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.71 | -16.82 % | $ 3.87 M | China |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
11.2 B | $ 197.56 | 1.05 % | $ 28.9 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.47 | -1.12 % | $ 8.35 B |  Australia |
 |
Bristol-Myers Squibb Company
BMY
|
71.5 B | $ 60.75 | 1.49 % | $ 124 B | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 107.57 | 1.76 % | $ 27.2 B | Germany |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 219.1 | 0.46 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
161 M | $ 40.16 | 4.73 % | $ 4.15 B | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.42 | 2.9 % | $ 362 M | Britain |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 9.38 | 0.86 % | $ 1.5 B | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 14.91 | 1.92 % | $ 4.61 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 53.36 | 9.05 % | $ 4.8 B |  Schweiz |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |